Free Trial

Insmed (NASDAQ:INSM) Given New $112.00 Price Target at The Goldman Sachs Group

Insmed logo with Medical background

Insmed (NASDAQ:INSM - Free Report) had its price objective boosted by The Goldman Sachs Group from $100.00 to $112.00 in a report released on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company's stock.

Other equities analysts have also recently issued research reports about the company. Bank of America raised their price objective on Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a report on Wednesday. UBS Group reduced their price objective on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a report on Friday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. Truist Financial upped their target price on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Finally, Morgan Stanley upped their price target on shares of Insmed from $90.00 to $102.00 and gave the stock an "overweight" rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Insmed presently has an average rating of "Moderate Buy" and an average price target of $104.81.

Check Out Our Latest Research Report on INSM

Insmed Price Performance

Shares of INSM stock traded up $1.85 during trading hours on Wednesday, hitting $98.73. The company had a trading volume of 5,318,455 shares, compared to its average volume of 2,164,284. The firm has a market capitalization of $17.98 billion, a price-to-earnings ratio of -17.66 and a beta of 0.80. Insmed has a 12 month low of $60.40 and a 12 month high of $100.00. The firm's fifty day moving average is $71.41 and its 200 day moving average is $73.61. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm's quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.06) earnings per share. On average, sell-side analysts predict that Insmed will post -4.56 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, CEO William Lewis sold 18,750 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the transaction, the chief executive officer now directly owns 334,186 shares in the company, valued at approximately $25,742,347.58. The trade was a 5.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Sara Bonstein sold 8,870 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total transaction of $601,474.70. Following the completion of the sale, the chief financial officer now directly owns 109,993 shares in the company, valued at $7,458,625.33. This trade represents a 7.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 319,932 shares of company stock worth $25,733,693 over the last three months. Corporate insiders own 3.00% of the company's stock.

Hedge Funds Weigh In On Insmed

A number of large investors have recently made changes to their positions in INSM. Cullen Frost Bankers Inc. boosted its position in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares during the last quarter. Elequin Capital LP bought a new stake in shares of Insmed in the fourth quarter worth $28,000. Steward Partners Investment Advisory LLC increased its stake in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC increased its stake in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares during the last quarter. Finally, NBC Securities Inc. bought a new stake in Insmed during the first quarter valued at $49,000.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Stories

Analyst Recommendations for Insmed (NASDAQ:INSM)

Should You Invest $1,000 in Insmed Right Now?

Before you consider Insmed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.

While Insmed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines